U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Amyotrophic lateral sclerosis with polyglucosan bodies

MedGen UID:
347953
Concept ID:
C1859805
Disease or Syndrome
Synonym: Amyotrophic Lateral Sclerosis With Polyglucosan Bodies
 
Monarch Initiative: MONDO:0008782
OMIM®: 205250

Clinical features

From HPO
Amyotrophic lateral sclerosis
MedGen UID:
274
Concept ID:
C0002736
Disease or Syndrome
Amyotrophic lateral sclerosis (ALS) is a progressive disease that affects motor neurons, which are specialized nerve cells that control muscle movement. These nerve cells are found in the spinal cord and the brain. In ALS, motor neurons die (atrophy) over time, leading to muscle weakness, a loss of muscle mass, and an inability to control movement.\n\nThere are many different types of ALS; these types are distinguished by their signs and symptoms and their genetic cause or lack of clear genetic association. Most people with ALS have a form of the condition that is described as sporadic, which means it occurs in people with no apparent history of the disorder in their family. People with sporadic ALS usually first develop features of the condition in their late fifties or early sixties. A small proportion of people with ALS, estimated at 5 to 10 percent, have a family history of ALS or a related condition called frontotemporal dementia (FTD), which is a progressive brain disorder that affects personality, behavior, and language. The signs and symptoms of familial ALS typically first appear in one's late forties or early fifties. Rarely, people with familial ALS develop symptoms in childhood or their teenage years. These individuals have a rare form of the disorder known as juvenile ALS.\n\nThe first signs and symptoms of ALS may be so subtle that they are overlooked. The earliest symptoms include muscle twitching, cramping, stiffness, or weakness. Affected individuals may develop slurred speech (dysarthria) and, later, difficulty chewing or swallowing (dysphagia). Many people with ALS experience malnutrition because of reduced food intake due to dysphagia and an increase in their body's energy demands (metabolism) due to prolonged illness. Muscles become weaker as the disease progresses, and arms and legs begin to look thinner as muscle tissue atrophies. Individuals with ALS eventually lose muscle strength and the ability to walk. Affected individuals eventually become wheelchair-dependent and increasingly require help with personal care and other activities of daily living. Over time, muscle weakness causes affected individuals to lose the use of their hands and arms. Breathing becomes difficult because the muscles of the respiratory system weaken. Most people with ALS die from respiratory failure within 2 to 10 years after the signs and symptoms of ALS first appear; however, disease progression varies widely among affected individuals.\n\nApproximately 20 percent of individuals with ALS also develop FTD. Changes in personality and behavior may make it difficult for affected individuals to interact with others in a socially appropriate manner. Communication skills worsen as the disease progresses. It is unclear how the development of ALS and FTD are related. Individuals who develop both conditions are diagnosed as having ALS-FTD.\n\nA rare form of ALS that often runs in families is known as ALS-parkinsonism-dementia complex (ALS-PDC). This disorder is characterized by the signs and symptoms of ALS, in addition to a pattern of movement abnormalities known as parkinsonism, and a progressive loss of intellectual function (dementia). Signs of parkinsonism include unusually slow movements (bradykinesia), stiffness, and tremors. Affected members of the same family can have different combinations of signs and symptoms.
Bulbar signs
MedGen UID:
347246
Concept ID:
C1856507
Finding
Distal muscle weakness
MedGen UID:
140883
Concept ID:
C0427065
Finding
Reduced strength of the musculature of the distal extremities.
Muscular atrophy
MedGen UID:
892680
Concept ID:
C0541794
Pathologic Function
The presence of skeletal muscular atrophy (which is also known as amyotrophy).

Recent clinical studies

Etiology

Hellmann MA, Kakhlon O, Landau EH, Sadeh M, Giladi N, Schlesinger I, Kidron D, Abramsky O, Reches A, Argov Z, Rabey JM, Chapman J, Rosenmann H, Gal A, Moshe Gomori J, Meiner V, Lossos A
J Neurol 2015 Oct;262(10):2346-51. Epub 2015 Jul 21 doi: 10.1007/s00415-015-7859-4. PMID: 26194201

Diagnosis

Hellmann MA, Kakhlon O, Landau EH, Sadeh M, Giladi N, Schlesinger I, Kidron D, Abramsky O, Reches A, Argov Z, Rabey JM, Chapman J, Rosenmann H, Gal A, Moshe Gomori J, Meiner V, Lossos A
J Neurol 2015 Oct;262(10):2346-51. Epub 2015 Jul 21 doi: 10.1007/s00415-015-7859-4. PMID: 26194201
McDonald TD, Faust PL, Bruno C, DiMauro S, Goldman JE
Neurology 1993 Apr;43(4):785-90. doi: 10.1212/wnl.43.4.785. PMID: 8469341

Therapy

Hirano A, Donnenfeld H, Sasaki S, Nakano I
J Neuropathol Exp Neurol 1984 Sep;43(5):461-70. doi: 10.1097/00005072-198409000-00001. PMID: 6540799

Prognosis

Robitaille Y, Carpenter S, Karpati G, DiMauro SD
Brain 1980 Jun;103(2):315-36. doi: 10.1093/brain/103.2.315. PMID: 6249438

Clinical prediction guides

Hirano A, Donnenfeld H, Sasaki S, Nakano I
J Neuropathol Exp Neurol 1984 Sep;43(5):461-70. doi: 10.1097/00005072-198409000-00001. PMID: 6540799

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...